 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Regeneron Pharmaceuticals, Inc.
 |
Regeneron Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Regeneron loss widens, will advance Axokine tests Jul 31 2001 01:45 PM PDT
Egypt's Orascom to invest $500 mln in Algeria-CEO Jul 31 2001 01:45 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Regeneron isn't the Pentagon, but the firm is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to treat a variety of diseases and conditions, including cancer, asthma, and even constipation. The firm focuses on discovering and developing neurotrophic factors, proteins required for neurons (nerve cells) to survive. It is developing several drug candidates based on its neurotrophic research; its lead candidate, AXOKINE, targets obesity and related adult-onset diabetes. Most of Regeneron's revenues come from contract R&D agreements it has with such firms as Proctor & Gamble, Amgen, and Medarex. Its also has a contract manufacturing deal with Merck.
COMPETITION |
 |
Hoffmann-La Roche Inc. (dossier)
Knoll GmbH (dossier)
NeoTherapeutics, Inc. (NEOT)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 59.30
1-Yr. Sales Growth: 71.9%
Employees: 491
Revenue per employee: $120,773.93
KEY PEOPLE |
 |
Leonard S. Schleifer
CEO
Murray A. Goldberg
CFO
CONTACT INFO |
 |
777 Old Saw Mill River Rd.
Tarrytown, NY 10591
US
Phone: 914-345-7400
Fax: 914-347-2113
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |